Pharmacokinetic and pharmacodynamic variability: A daunting challenge in drug therapy

被引:52
作者
Lin, Jiunn H. [1 ]
机构
[1] Merck Sharp & Dohme Ltd, Res Labs, Dept Preclin Drug Metab, West Point, PA 19486 USA
关键词
D O I
10.2174/138920007779816002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Patients vary considerably in their response to drug therapy. A drug that proves to be pharmacologically effective in some patients at a given dose may be ineffective or even toxic in others. The interindividual variability in drug response represents a major challenge in drug therapy, particularly for drugs with narrow therapeutic index. The intensity and duration of a drug action are determined not only by pharmacokinetic processes, but also by pharmacodynamic processes. Therefore, the variability in drug response is a result of the variability in either pharmacokinetic or pharmacodynamic processes, or a combination of both. The purpose of this paper is to review the sources that contribute to pharmacokinetic and pharmacodynamic variability. Although the main focus will be on the genetic variability, the impact of environmental factors on drug response will also be discussed. Finally, the application and limitation of the concept of personalized medicine will be briefly discussed.
引用
收藏
页码:109 / 136
页数:28
相关论文
共 328 条
[101]   Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity [J].
Ingelman-Sundberg, M .
PHARMACOGENOMICS JOURNAL, 2005, 5 (01) :6-13
[102]   Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future [J].
Ingelman-Sundberg, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (04) :193-200
[103]   The effect of polymorphisms of the β2-adrenergic receptor on the response to regular use of albuterol in asthma [J].
Israel, E ;
Drazen, JM ;
Liggett, SB ;
Boushey, HA ;
Cherniack, RM ;
Chinchilli, VM ;
Cooper, DM ;
Fahy, JV ;
Fish, JE ;
Ford, JG ;
Kraft, M ;
Kunselman, S ;
Lazarus, SC ;
Lemanske, RF ;
Martin, RJ ;
McLean, DE ;
Peters, SP ;
Silverman, EK ;
Sorkness, CA ;
Szefler, SJ ;
Weiss, ST ;
Yandava, CN .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (01) :75-80
[104]   Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2 [J].
Ito, K ;
Suzuki, H ;
Sugiyama, Y .
MOLECULAR PHARMACOLOGY, 2001, 59 (05) :1077-1085
[105]   Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals:: An association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28 [J].
Itoda, M ;
Saito, Y ;
Soyama, A ;
Saeki, M ;
Murayama, N ;
Ishida, S ;
Sai, K ;
Nagano, M ;
Suzuki, H ;
Sugiyama, Y ;
Ozawa, S ;
Sawada, J .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (04) :363-364
[106]  
Itoda Masaya, 2004, Drug Metab Pharmacokinet, V19, P308, DOI 10.2133/dmpk.19.308
[107]   UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity [J].
Iyer L. ;
Das S. ;
Janisch L. ;
Wen M. ;
Ramírez J. ;
Karrison T. ;
Fleming G.F. ;
Vokes E.E. ;
Schilsky R.L. ;
Ratain M.J. .
The Pharmacogenomics Journal, 2002, 2 (1) :43-47
[108]  
Jackson E. K., 2006, GOODMAN GILMANS PHAR, P789
[109]  
Jackson EK, 2001, GOODMAN GILMANS PHAR, P809
[110]   DOXORUBICIN AND DOXORUBICINOL - INTRAINDIVIDUAL AND INTERINDIVIDUAL VARIATIONS OF PHARMACOKINETIC PARAMETERS [J].
JACQUET, JM ;
BRESSOLLE, F ;
GALTIER, M ;
BOURRIER, M ;
DONADIO, D ;
JOURDAN, J ;
ROSSI, JF .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 27 (03) :219-225